Skip to main content
Apr 30, 2003

Stock surveillance & targeting

How IR sleuthing has evolved from art to science

Catherine Forte remembers the 'old days'. 'We would pore over reams of Technimetrics listings, highlighting any fund manager running enough money to fit our investment parameters,' recalls the IR veteran, now associate director of IR at biotech firm Genzyme. 'Investment styles such as growth and value were not an issue. Afterward, we would consult the Nelson's books to read the investment manager profile, hoping it was up to date. That's how you made targeting assessments.' Since that time

To continue reading you need an active subscription

  • Quarterly issues of IR Magazine
  • Unlimited Articles online
  • Newsletter
  • Investor Perception Studies – Europe, US, Canada and Asia
  • Strategy guides
  • Whitepapers
  • Benchmarking reports
From $995*